BioNTech Heads to ASCO With a Cash Pile and a Cloud of Doubt
23.05.2026 - 22:32:25 | boerse-global.de
When BioNTech’s scientists take the stage in Chicago next week, they will be armed with two sets of clinical data and roughly €16.8 billion in cash. What they cannot bring is the market’s full confidence — and that gap may be the most important story of the ASCO meeting.
The German biotech’s shares closed at €79.50 on Friday, a 1.53% gain for the day but still 22% below the 52-week high and 8.06% beneath the 200-day moving average. Over the past month the stock has shed 15.25%, a reminder that the positive trading sessions remain isolated events in a broader downtrend.
That cautious mood was cemented just before the data drop when Bernstein initiated coverage with a “Market Perform” rating and a price target of $96 — well under the consensus view of roughly $125. The firm pointed to historical setbacks with PD-L1/VEGF agents and argued that market expectations for that drug class are too rosy, given BioNTech’s ambitious clinical timetable.
Pipeline Takes Centre Stage
The ASCO annual meeting runs from 29 May to 2 June, and BioNTech has scheduled formal presentations for its two lead oncology candidates on 30 May. The most anticipated dataset is for pumitamig (BNT327), a bispecific immune modulator developed jointly with Bristol Myers Squibb. Interim results from the global ROSETTA-Lung-02 trial show encouraging antitumour activity in first-line non-small cell lung cancer when combined with chemotherapy. This is the third global dataset for the molecule, and it reinforces a signal that has now been seen across multiple tumour types.
Should investors sell immediately? Or is it worth buying BioNTech?
Alongside pumitamig comes gotistobart (BNT311), a CTLA-4 antibody for which BioNTech will present Phase 2 overall survival data in platinum-resistant ovarian cancer. The company describes the results as showing durable antitumour activity and clinically meaningful survival with a manageable safety profile — a potential chemotherapy-free option for heavily pretreated patients.
Beyond those two programmes, BioNTech will display several antibody-drug conjugates across ongoing study posters. The breadth of the pipeline is striking: more than 25 Phase 2 and Phase 3 studies are underway, with 13 currently classified as pivotal.
Restructuring and Red Ink
The oncology push comes as BioNTech reshapes its cost base. The company is closing multiple production sites and cutting roughly 1,860 jobs by October 2026, targeting annual savings of around €500 million — though those benefits are not expected to materialise until 2029.
The financial numbers for the first quarter of 2026 highlight the urgency: a net loss of €531.9 million. Full-year revenue is forecast between €2.0 billion and €2.3 billion, a fraction of the Covid-era peak.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Still, the balance sheet offers plenty of runway. With €16.8 billion in liquidity, BioNTech can fund its entire late-stage pipeline for the foreseeable future. The question that ASCO will help answer is whether that money is being spent on winners.
If pumitamig and gotistobart deliver a strong clinical profile relative to competitors, the scepticism that has kept the stock pinned below moving averages may begin to fade. If the data underwhelms, the job cuts and the cash burn will only magnify the pressure. For now, all eyes are on the Chicago stage — and on the 30th of May.
Ad
BioNTech Stock: New Analysis - 23 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
